We’ve been partnering with small biotech companies since our beginning.
PRA wouldn’t be where it is today without the nimbleness and expertise we earned working with biotech. We’re big because we started off small and focused, growing intelligently over the years and now able to run trials in more than 90 countries.
This steady evolution has allowed us to partner with big companies, but our roots and work with biotech never changed.
Our teams are trained, experienced, and passionate about the work they do. We’ve partnered with more than 500 sponsors over the last 5 years, with over 70% of PRA’s clients being small and medium biopharma companies.
Biotech is in our DNA.
Biotech is a part of our heritage. We’re built for—and remain focused on—creating customized strategic, operational, and commercial solutions for emerging biopharma clients.
Our handpicked teams have a passion for cutting-edge research and enjoy partnering with biotech clients. They’re driven by an entrepreneurial mindset that empowers common sense decisions, focused on delivery.
Our biotech services
PRA is an effective partner due to our flat management structure, agility, entrepreneurial mindset, and extensive experience working with emerging and mid-sized biotech. We support small and emerging companies across the drug continuum from Pre-IND through to post-approval. Our services include:
- Asset Valuation
- Regulatory Strategy
- Drug Development Strategy
- Phase I-III Study Planning and Clinical Operations
- Staff Augmentation and Functional Services Provider
Our experience starts at the earliest stages of the drug development continuum and overall development strategy, continuing through clinical development and post-marketing support. Not only do our operations teams bring proactive solutions to mitigate potential risks, our supportive and business management teams have the know-how to develop pricing models and incentives that align with the unique financial needs of biotech clients.Contact us to discuss your biotech needs.
Expertise in your hands.
PRA understands the pressures emerging biotech companies face. We resource client studies with team leads that remain for the duration of the study and offer strategic guidance based on your unique goals. This puts us in a position to best identify every opportunity that supports your success.
We also know how important it is to have executive leadership involved. Our General Partners provide executive support to over 100 of our biotech clients, providing an experienced leader for peer-to-peer consulting and problem-solving.
PRA supports biotech as a core element of our company. Our entrepreneurial mindset and biotech-focused training ensures we deliver comprehensive, tailored, and flexible solutions to our biotech clients.
Demystifying Pediatric Clinical Research for Emerging Biotech
A substantial change to the drug development landscape is currently underway. Regulatory authorities are starting to acknowledge pediatrics as one of…
Chemistry, Manufacturing, and Controls (CMC) in Drug Development and Life Cycle Management
This white paper provides biotech companies an overview of the considerations for Chemistry, Manufacturing and Controls (CMC) in asset development.…
5 Questions Small Biotech Should Ask Their Rare Disease Development Partner
Rare disease is a complicated but rewarding space for drug developers of all sizes. Most rare diseases have no approved treatment options, making…